For decades, lung cancer has carried a grim arithmetic: the later it is found, the less can be done. A team of researchers spanning four institutions has now developed a protein-based MRI contrast agent capable of detecting tumors as small as one millimeter — without radiation — by targeting the collagen signature of aggressive disease. It is a quiet but consequential shift in the oldest challenge of oncology: finding the enemy before it has already moved.
Protein-based MRI agent detects lung cancer tumors as small as 1mm without radiation
Earlier detection of lung cancer could improve patient outcomes by enabling treatment at earlier, more treatable stages when options are less limited.